Difference between revisions of "Temsirolimus (Torisel)"
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://labeling.pfizer.com/showlabeling.aspx?ID=490 Temsirolimus (Torisel) package insert]</ref><ref>[http://hemonc.o...") |
|||
Line 1: | Line 1: | ||
+ | Also known as CCI-779. | ||
+ | |||
==General information== | ==General information== | ||
− | Class/mechanism: <ref name="insert">[http://labeling.pfizer.com/showlabeling.aspx?ID=490 Temsirolimus (Torisel) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/temsirolimus.pdf Temsirolimus (Torisel) package insert (locally hosted backup)]</ref> | + | Class/mechanism: mTOR (mammalian target of rapamycin) inhibitor. mTOR inhibition by temsirolimus interferes with the ability of mTOR to phosphorylate downstream targets in the PI3 kinase/AKT pathway, such as p70S6k and the S6 ribosomal protein. Temsirolimus has also been observed to reduce levels of VEGF (vascular endothelial growth factor) and hypoxia-inducible factors HIF-1 and HIF-2 alpha.<ref name="insert">[http://labeling.pfizer.com/showlabeling.aspx?ID=490 Temsirolimus (Torisel) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/temsirolimus.pdf Temsirolimus (Torisel) package insert (locally hosted backup)]</ref><ref>[http://torisel.com/ Torisel manufacturer's website]</ref> |
− | <br>Route: | + | <br>Route: IV |
− | <br>Extravasation: | + | <br>Extravasation: no information |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
==Patient drug information== | ==Patient drug information== | ||
− | *[http://chemocare.com/bio/temsirolimus. | + | *[http://chemocare.com/bio/temsirolimus.asp Temsirolimus (Torisel) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/temsirolimus.asp Temsirolimus (Torisel) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/temsirolimus-patient-drug-information Temsirolimus (Torisel) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/temsirolimus-patient-drug-information Temsirolimus (Torisel) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/temsirolimus-patient-drug-information Temsirolimus (Torisel) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/temsirolimus-patient-drug-information Temsirolimus (Torisel) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> |
Revision as of 23:35, 24 February 2012
Also known as CCI-779.
General information
Class/mechanism: mTOR (mammalian target of rapamycin) inhibitor. mTOR inhibition by temsirolimus interferes with the ability of mTOR to phosphorylate downstream targets in the PI3 kinase/AKT pathway, such as p70S6k and the S6 ribosomal protein. Temsirolimus has also been observed to reduce levels of VEGF (vascular endothelial growth factor) and hypoxia-inducible factors HIF-1 and HIF-2 alpha.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Temsirolimus (Torisel) patient drug information (Chemocare)[4]
- Temsirolimus (Torisel) patient drug information (UpToDate)[5]